Proton pump inhibitors for personified treatment of laryngopharyngeal reflux patients without symptoms of gastroesophageal disease
Анготоева И. Б., Лоранскайа И. Д., Косяков С. Y., Карева Е. Н.
Экспериментальная и клиническая фармакология
Т. 82, Вып. 3, С. 7-12
Опубликовано: 2019
Тип ресурса: Статья
DOI:10.30906/0869-2092-2019-82-3-7-12
Аннотация:
The treatment of patients with laryngopharyngeal reflux (LPR) without symptoms of gastroesophagitis reflux disease (GERD) is a topical problem that still re mains unresolved. Despite the fact that both LPR and GERD have much in common in their pathogenesis, the hypoacidic therapy shows different efficacy for these symptoms. That is, while GERD can be highly efficiently treated with proton pump inhibitors as monotherapy, the results in patients with LPR without GERD symptoms are rather controversial. In this paper, we discuss potential reasons of treatment failure in patients with the latter disease. Besides the extrinsic reasons such as compliance, recommended schedule violation, and drug product quality, we also focus on individual patients' peculiarities like the proton pump inhibitor metabolism rate. One of the possible reasons of proton pump inhibitor failure in patients with LPR without symptoms of GERD might be CYP2C19 allele polymorphism in these patients, which leads to rapid p
Ключевые слова:
Cyp2c19 gene polymorphism; Laryngopharyngeal reflux; Proton pump inhibitors
proton pump inhibitor; allele; Article; drug efficacy; drug metabolism; drug quality; gastroesophageal reflux; human; laryngopharyngeal reflux; medication compliance; metabolic rate; monotherapy; pathogenesis; product quality; symptom; treatment failure
Язык текста: Русский
ISSN: 0869-2092
Анготоева И. Б.
Лоранскайа И. Д.
Косяков С. Y. С.Я.
Карева Е. Н. Елена Николаевна 1961-
Angotoeva I. B.
Loranskaya I. D.
Kosyakov S. Y. S.Ya.
Kareva E. N. Elena Nikolaevna 1961-
Proton pump inhibitors for personified treatment of laryngopharyngeal reflux patients without symptoms of gastroesophageal disease
Текст визуальный непосредственный
Экспериментальная и клиническая фармакология
ООО "Фолиум"
Т. 82, Вып. 3 С. 7-12
2019
Статья
Cyp2c19 gene polymorphism Laryngopharyngeal reflux Proton pump inhibitors
proton pump inhibitor allele Article drug efficacy drug metabolism drug quality gastroesophageal reflux human laryngopharyngeal reflux medication compliance metabolic rate monotherapy pathogenesis product quality symptom treatment failure
The treatment of patients with laryngopharyngeal reflux (LPR) without symptoms of gastroesophagitis reflux disease (GERD) is a topical problem that still re mains unresolved. Despite the fact that both LPR and GERD have much in common in their pathogenesis, the hypoacidic therapy shows different efficacy for these symptoms. That is, while GERD can be highly efficiently treated with proton pump inhibitors as monotherapy, the results in patients with LPR without GERD symptoms are rather controversial. In this paper, we discuss potential reasons of treatment failure in patients with the latter disease. Besides the extrinsic reasons such as compliance, recommended schedule violation, and drug product quality, we also focus on individual patients' peculiarities like the proton pump inhibitor metabolism rate. One of the possible reasons of proton pump inhibitor failure in patients with LPR without symptoms of GERD might be CYP2C19 allele polymorphism in these patients, which leads to rapid p